Parkinson's disease: emerging pharmacotherapy

Bibliography

• de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5(6):525-35
   PubMed Web of Science ®Google Scholar
• Sian J, Gerlach M, Youdim MB, Riederer P. Parkinson's disease: a major hypokinetic basal ganglia disorder. J Neural Transm 1999;106(5-6):443-76
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K. Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology 2008;70(20):1916-25
   PubMed Web of Science ®Google Scholar
• Kovacs GG, Kloppel S, Fischer I, et al. Nucleus-specific alteration of raphe neurons in human neurodegenerative disorders. Neuroreport 2003;14(1):73-6
   PubMed Web of Science ®Google Scholar
• Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 2003;60(3):337-41
   PubMed Web of Science ®Google Scholar
• Rascol O, Payoux P, Ory F, et al. Limitations of current Parkinson's disease therapy. Ann Neurol 2003;53(Suppl 3):S3-12; discussion S-5
   PubMed Web of Science ®Google Scholar
• Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79(4):368-76
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55(3):181-4
   PubMed Web of Science ®Google Scholar
• Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003;18(5):467-86
   PubMed Web of Science ®Google Scholar
• Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol 2008;15(Suppl 1):14-20
   PubMed Web of Science ®Google Scholar
• Santamaria J, Tolosa E, Valles A. Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 1986;36(8):1130-3
   PubMed Web of Science ®Google Scholar
• Stiasny-Kolster K, Doerr Y, Moller JC, et al. Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005;128(Pt 1):126-37
   PubMed Web of Science ®Google Scholar
• Ponsen MM, Stoffers D, Booij J, et al. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004;56(2):173-81
   PubMed Web of Science ®Google Scholar
• Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20(2):190-9
   PubMed Web of Science ®Google Scholar
• The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18(7):738-50
   PubMed Web of Science ®Google Scholar
• Greenamyre JT, Betarbet R, Sherer TB. The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism Relat Disord 2003;9(Suppl 2):S59-64
   PubMed Web of Science ®Google Scholar
• Shults CW, Haas RH, Passov D, Beal MF. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol 1997;42(2):261-4
   PubMed Web of Science ®Google Scholar
• Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989;52(6):1830-6
   PubMed Web of Science ®Google Scholar
• Schapira AH, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990;54(3):823-7
   PubMed Web of Science ®Google Scholar
• Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989;52(2):515-20
   PubMed Web of Science ®Google Scholar
• Holtz WA, O'Malley KL. Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. J Biol Chem 2003;278(21):19367-77
   PubMed Web of Science ®Google Scholar
• Imai Y, Soda M, Inoue H, et al. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 2001;105(7):891-902
   PubMed Web of Science ®Google Scholar
• Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 2008;131(Pt 8):1969-78
   PubMed Web of Science ®Google Scholar
• Brice A. Genetics of Parkinson's disease: LRRK2 on the rise. Brain 2005;128(Pt 12):2760-2
   PubMed Web of Science ®Google Scholar
• Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392(6676):605-8
   PubMed Web of Science ®Google Scholar
• Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004;304(5674):1158-60
   PubMed Web of Science ®Google Scholar
• Takahashi H, Wakabayashi K. The cellular pathology of Parkinson's disease. Neuropathology 2001;21(4):315-22
   PubMed Web of Science ®Google Scholar
• Farrer M, Chan P, Chen R, et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 2001;50(3):293-300
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 2004;111(10-11):1219-35
   PubMed Web of Science ®Google Scholar
• Schapira AH. Progress in neuroprotection in Parkinson's disease. Eur J Neurol 2008;15(Suppl 1):5-13
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O. Early Rasagiline Treatment Slows UPDRS decline in the ADAGIO delayed start study. ANA annual meeting; 2008. 133rd Annual Meeting of the American Neurological Association (ANA), 23rd September 2008
   Google Scholar
• da Silva-Junior FP, Braga-Neto P, Sueli Monte F, de Bruin VM. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord 2005;11(7):449-52
   PubMed Web of Science ®Google Scholar
• Palhagen SE, Carlsson M, Curman E, et al. Depressive illness in Parkinson's disease - indication of a more advanced and widespread neurodegenerative process? Acta Neurol Scand 2008;117(5):295-304
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351(24):2509-18
   PubMed Web of Science ®Google Scholar
• Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005;20(8):958-63
   PubMed Web of Science ®Google Scholar
• Clarke CE, Guttman M. Dopamine agonist monotherapy in Parkinson's disease. Lancet 2002;360(9347):1767-9
   PubMed Web of Science ®Google Scholar
• Subramony JA. Apomorphine in dopaminergic therapy. Mol Pharm 2006;3(4):380-5
   PubMed Web of Science ®Google Scholar
• Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2004;4:CD004554
   Google Scholar
• Muller T, Kuhn W, Przuntek H. Efficacy of budipine and placebo in untreated patients with Parkinson's disease. J Neural Transm 2005;112(8):1015-23
   PubMed Web of Science ®Google Scholar
• Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004;19(9):997-1005
   PubMed Web of Science ®Google Scholar
• Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003;54(1):93-101
   PubMed Web of Science ®Google Scholar
• Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287(13):1653-61
   PubMed Web of Science ®Google Scholar
• Mytilineou C, Han SK, Cohen G. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem 1993;61(4):1470-8
   PubMed Web of Science ®Google Scholar
• Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007;22(16):2409-17
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008;71(7):474-80
   PubMed Web of Science ®Google Scholar
• Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351(24):2498-508
   PubMed Web of Science ®Google Scholar
• Stowe RL, Ives NJ, Clarke C, et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2008;2:CD006564
   PubMed Web of Science ®Google Scholar
• Inzelberg R, Schechtman E, Nisipeanu P. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Drugs Aging 2003;20(11):847-55
   PubMed Web of Science ®Google Scholar
• Nyholm D, Constantinescu R, Holmberg B, et al. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. Acta Neurol Scand 2008 Sep 24. [Epub ahead of print]
   Google Scholar
• Antonini A. Continuous dopaminergic stimulation: from theory to clinical practice. Parkinsonism Relat Disord 2007;13(Suppl):S24-8
   PubMed Web of Science ®Google Scholar
• van Laar T, Jansen EN, Essink AW, et al. A double-blind study of the efficacy of apomorphine and its assessment in ‘off’-periods in Parkinson's disease. Clin Neurol Neurosurg 1993;95(3):231-5
   PubMed Web of Science ®Google Scholar
• Corsini GU, Del Zompo M, Gessa GL, Mangoni A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet 1979;1(8123):954-6
   PubMed Web of Science ®Google Scholar
• Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 2002;17(6):1235-41
   PubMed Web of Science ®Google Scholar
• Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry 1998;65(5):709-16
   PubMed Web of Science ®Google Scholar
• Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 2000;59(6):1233-50
   PubMed Web of Science ®Google Scholar
• Keating GM, Lyseng-Williamson KA. Tolcapone: a review of its use in the management of Parkinson's disease. CNS Drugs 2005;19(2):165-84
   PubMed Web of Science ®Google Scholar
• Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease. Mov Disord 2007;22(1):14-9
   PubMed Web of Science ®Google Scholar
• Thebault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy 2004;24(10):1295-305
   PubMed Web of Science ®Google Scholar
• Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001;132(2):500-6
   PubMed Web of Science ®Google Scholar
• Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. Ann Neurol 1996;39(1):37-45
   PubMed Web of Science ®Google Scholar
• Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38(5):771-7
   PubMed Web of Science ®Google Scholar
• Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20(5):523-39
   PubMed Web of Science ®Google Scholar
• Waters CH, Sethi KD, Hauser RA, et al. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004;19(4):426-32
   PubMed Web of Science ®Google Scholar
• Finberg JP, Youdim MB. Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology 2002;43(7):1110-8
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Chen JJ. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. Clin Neuropharmacol 2007;30(3):150-68
   PubMed Web of Science ®Google Scholar
• A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62(2):241-8
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365(9463):947-54
   PubMed Web of Science ®Google Scholar
• Marks WJ Jr, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, Phase I trial. Lancet Neurol 2008;7(5):400-8
   PubMed Web of Science ®Google Scholar
• Hodaie M, Neimat JS, Lozano AM. The dopaminergic nigrostriatal system and Parkinson's disease: molecular events in development, disease, and cell death, and new therapeutic strategies. Neurosurgery 2007;60(1):17-28; discussion 30
   PubMed Web of Science ®Google Scholar
• Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 2008;9(9):665-77
   PubMed Web of Science ®Google Scholar
• Yang M, Soohoo D, Soelaiman S, et al. Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists. Naunyn Schmiedebergs Arch Pharmacol 2007;375(2):133-44
   PubMed Web of Science ®Google Scholar
• Castagnoli N Jr, Petzer JP, Steyn S, et al. Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists. Neurology 2003;61(11 Suppl 6):S62-8
   PubMedGoogle Scholar
• Bara-Jimenez W, Sherzai A, Dimitrova T, et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003;61(3):293-6
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces ‘off’ time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008;63(3):295-302
   PubMed Web of Science ®Google Scholar
• Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 2008;70(23):2233-40
   PubMed Web of Science ®Google Scholar
• Lyons KE, Pahwa R. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. Clin Neuropharmacol 2006;29(3):148-53
   PubMed Web of Science ®Google Scholar
• Murata M. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des 2004;10(6):687-93
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Sullivan KL, Maldonado JL, et al. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2005;20(9):1205-9
   PubMed Web of Science ®Google Scholar
• Murata M, Hasegawa K, Kanazawa I. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 2007;68(1):45-50
   PubMed Web of Science ®Google Scholar
• Konitsiotis S, Blanchet PJ, Verhagen L, et al. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 2000;54(8):1589-95
   PubMed Web of Science ®Google Scholar
• Klockgether T, Turski L, Honore T, et al. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol 1991;30(5):717-23
   PubMed Web of Science ®Google Scholar
• Luquin MR, Obeso JA, Laguna J, et al. The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys. Eur J Pharmacol 1993;235(2-3):297-300
   PubMed Web of Science ®Google Scholar
• Elting JW, Sulter GA, Kaste M, et al. AMPA antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell toxicity detected by monitoring of S-100B serum levels. Stroke 2002;33(12):2813-8
   PubMed Web of Science ®Google Scholar
• Nutt JG, Gunzler SA, Kirchhoff T, et al. Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism. Mov Disord 2008
   Google Scholar
• Wessell RH, Ahmed SM, Menniti FS, et al. NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology 2004;47(2):184-94
   PubMed Web of Science ®Google Scholar
• Nash JE, Ravenscroft P, McGuire S, et al. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 2004;188(2):471-9
   PubMed Web of Science ®Google Scholar
• Lees KR. Cerestat and other NMDA antagonists in ischemic stroke. Neurology 1997;49(5 Suppl 4):S66-9
   PubMed Web of Science ®Google Scholar
• Glennon JC, Van Scharrenburg G, Ronken E, et al. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist. Synapse 2006;60(8):599-608
   PubMed Web of Science ®Google Scholar
• Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 2002;58(4 Suppl 1):S1-8
   PubMed Web of Science ®Google Scholar
• Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001;57(10):1829-34
   PubMed Web of Science ®Google Scholar
• Pot C, Oppliger R, Castillo V, et al. Apomorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease. Neurology 2005;64(2):392-3
   PubMed Web of Science ®Google Scholar
• Esteban Munoz J, Marti MJ, Marin C, Tolosa E. Long-term treatment with intermitent intranasal or subcutaneous apormorphine in patients with levodopa-related motor fluctuations. Clin Neuropharmacol 1997;20(3):245-52
   PubMed Web of Science ®Google Scholar
• Dewey RB, Jr, Maraganore DM, Ahlskog JE, Matsumoto JY. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease. Mov Disord 1998;13(5):782-7
   PubMed Web of Science ®Google Scholar
• Sam E, Jeanjean AP, Maloteaux JM, Verbeke N. Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. Eur J Drug Metab Pharmacokinet 1995;20(1):27-33
   PubMed Web of Science ®Google Scholar
• Neef C, Van Laar T. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin Pharmacokinet 1999;37(3):257-71
   PubMed Web of Science ®Google Scholar
• Stocchi F, Arnold G, Onofrj M, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology 2004;63(4):746-8
   PubMed Web of Science ®Google Scholar
• Caccia C, Maj R, Calabresi M, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 2006;67(7 Suppl 2):S18-23
   PubMed Web of Science ®Google Scholar
• Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75(5):689-95
   PubMed Web of Science ®Google Scholar
• Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson's disease. Mov Disord 1990;5(3):225-9
   PubMed Web of Science ®Google Scholar
• Vanover KE, Weiner DM, Makhay M, et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropylo xy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 2006;3172:910-8
   Web of Science ®Google Scholar
• Vanover KE, Betz AJ, Weber SM, et al. A 5-HT(2A) receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol Biochem Behav 2008;90(4):540-4
   PubMed Web of Science ®Google Scholar
• Gomez-Mancilla B, Bedard PJ. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 1993;16(5):418-27
   PubMed Web of Science ®Google Scholar
• Rascol O, Arnulf I, Peyro-Saint Paul H, et al. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord 2001;16(4):708-13
   PubMed Web of Science ®Google Scholar
• Savola JM, Hill M, Engstrom M, et al. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 2003;18(8):872-83
   PubMed Web of Science ®Google Scholar
• Meco G, Fabrizio E, Di Rezze S, et al. Mirtazapine in L-dopa-induced dyskinesias. Clin Neuropharmacol 2003;26(4):179-81
   PubMed Web of Science ®Google Scholar
• Garcia-Ladona FJ, Cox BF. BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction. CNS Drug Rev 2003;9(2):141-58
   PubMedGoogle Scholar
• Visanji NP, Millan MJ, Brotchie JM. Actions at sites other than D3; receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats. Exp Neurol 2006;202(1):85-92
   PubMed Web of Science ®Google Scholar
• Pollak L, Dobronevsky Y, Prohorov T, et al. Low dose methylphenidate improves freezing in advanced Parkinson's disease during off-state. J Neural Transm Suppl 2007;72:145-8
   PubMed Web of Science ®Google Scholar
• Devos D, Krystkowiak P, Clement F, et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78(5):470-5
   PubMed Web of Science ®Google Scholar
• A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007;68(1):20-8
   PubMed Web of Science ®Google Scholar
• Surmeier DJ. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol 2007;6(10):933-8
   PubMed Web of Science ®Google Scholar
• Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008;23(6):850-7
   PubMed Web of Science ®Google Scholar
• Harada CN, Shega JW, Sachs GA. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2005;352(13):1387; author reply
   PubMed Web of Science ®Google Scholar
• Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 2008;13(1):97-107
   PubMed Web of Science ®Google Scholar
• Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 1999;22(5):273-6
   PubMed Web of Science ®Google Scholar
• Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005;76(12):1636-9
   PubMed Web of Science ®Google Scholar
• Medeiros CA, Carvalhedo De Bruin PF, Lopes LA, et al. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study. J Neurol 2007;254(4):459-64
   PubMed Web of Science ®Google Scholar
• Zammit G, Erman M, Wang-Weigand S, et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007;3(5):495-504
   PubMed Web of Science ®Google Scholar
• Mathias CJ. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin Auton Res 2008;18(Suppl 1):25-9
   PubMed Web of Science ®Google Scholar
• Schrag A, Ben-Shlomo Y, Quinn N. How common are complications of Parkinson's disease? J Neurol 2002;249(4):419-23
   PubMed Web of Science ®Google Scholar
• Hauser RA, Mc Dermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006;63(12):1756-60
   PubMed Web of Science ®Google Scholar
• Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005;20(2):224-30
   PubMed Web of Science ®Google Scholar
• Riederer P, Gille G, Muller T, et al. Practical importance of neuroprotection in Parkinson's disease. J Neurol 2002;249(Suppl 3):III/53-6
   Google Scholar
• Bonnet AM, Loria Y, Saint-Hilaire MH, et al. Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology 1987;37(9):1539-42
   PubMed Web of Science ®Google Scholar
• Hagenah J, Klein C, Sieberer M, Vieregge P. Exogenous levodopa is not toxic to elderly subjects with non-parkinsonian movement disorders: further clinical evidence. J Neural Transm 1999;106(3-4):301-7
   PubMed Web of Science ®Google Scholar
• Boyce S, Rupniak NM, Steventon MJ, Iversen SD. Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clin Neuropharmacol 1990;13(5):448-58
   PubMed Web of Science ®Google Scholar
• Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996;53(12):1265-8
   PubMed Web of Science ®Google Scholar
• Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003;60(11):1756-61
   PubMed Web of Science ®Google Scholar
• Apaydin H, Ahlskog JE, Parisi JE, et al. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002;59(1):102-12
   PubMed Web of Science ®Google Scholar
• Mori S. Responses to donepezil in Alzheimer's disease and Parkinson's disease. Ann NY Acad Sci 2002;977:493-500
   PubMed Web of Science ®Google Scholar
• Asahina M, Suhara T, Shinotoh H, et al. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: A Positron Emission Tomographic study. J Neurol Neurosurg Psychiatry 1998;65(2):155-63
   PubMed Web of Science ®Google Scholar
• Aubert I, Araujo DM, Cecyre D, et al. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J Neurochem 1992;58(2):529-41
   PubMed Web of Science ®Google Scholar
• Nakano I, Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 1984;15(5):415-8
   PubMed Web of Science ®Google Scholar
• Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985;48(5):413-21
   PubMed Web of Science ®Google Scholar
• Werber EA, Rabey JM. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm 2001;108(11):1319-25
   PubMed Web of Science ®Google Scholar
• Burn D, Emre M, Mc Keith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006;21(11):1899-907
   PubMed Web of Science ®Google Scholar
• Quik M, Cox H, Parameswaran N, et al. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol 2007;62(6):588-96
   PubMed Web of Science ®Google Scholar
• Bordia T, Campos C, Huang L, Quik M. Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J Pharmacol Exp Ther 2008;327(1):239-47
   PubMed Web of Science ®Google Scholar
• Villafane G, Cesaro P, Rialland A, et al. Chronic high dose transdermal nicotine in Parkinson's disease: an open trial. Eur J Neurol 2007;14(12):1313-6
   PubMed Web of Science ®Google Scholar
• Voulalas PJ, Holtzclaw L, Wolstenholme J, et al. Metabotropic glutamate receptors and dopamine receptors cooperate to enhance extracellular signal-regulated kinase phosphorylation in striatal neurons. J Neurosci 2005;25(15):3763-73
   PubMed Web of Science ®Google Scholar
• Loftis JM, Janowsky A. The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol Ther 2003;97(1):55-85
   PubMed Web of Science ®Google Scholar
• Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 2003;6(5):501-6
   PubMed Web of Science ®Google Scholar
• Hurley MJ, Jackson MJ, Smith LA, et al. Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets. Eur J Neurosci 2005;21(12):3240-50
   PubMed Web of Science ®Google Scholar
• Dunah AW, Wang Y, Yasuda RP, et al. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol Pharmacol 2000;57(2):342-52
   PubMed Web of Science ®Google Scholar
• Calon F, Rajput AH, Hornykiewicz O, et al. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis 2003;14(3):404-16
   PubMed Web of Science ®Google Scholar
• Bernard V, Somogyi P, Bolam JP. Cellular, subcellular, and subsynaptic distribution of AMPA-type glutamate receptor subunits in the neostriatum of the rat. J Neurosci 1997;17(2):819-33
   PubMed Web of Science ®Google Scholar
• Marin C, Jimenez A, Bonastre M, et al. LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats. Synapse 2001;42(1):40-7
   PubMed Web of Science ®Google Scholar
• Lynch G, Baudry M. The biochemistry of memory: a new and specific hypothesis. Science 1984;224(4653):1057-63
   PubMed Web of Science ®Google Scholar
• Malenka RC, Nicoll RA. Long-term potentiation: a decade of progress? Science 1999;285(5435):1870-4
   PubMed Web of Science ®Google Scholar
• Baumbarger P, Muhlhauser M, Yang CR, Nisenbaum ES. LY392098, a novel AMPA receptor potentiator: electrophysiological studies in prefrontal cortical neurons. Neuropharmacology 2001;40(8):992-1002
   PubMed Web of Science ®Google Scholar
• Murray TK, Whalley K, Robinson CS, et al. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J Pharmacol Exp Ther 2003;306(2):752-62
   PubMed Web of Science ®Google Scholar
• Kish SJ, Tong J, Hornykiewicz O, et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008;131(Pt 1):120-31
   PubMed Web of Science ®Google Scholar
• De Deurwaerdere P, Navailles S, Berg KA, et al. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 2004;24(13):3235-41
   PubMed Web of Science ®Google Scholar
• Di Matteo V, Cacchio M, Di Giulio C, Esposito E. Role of serotonin(2C) receptors in the control of brain dopaminergic function. Pharmacol Biochem Behav 2002;71(4):727-34
   PubMed Web of Science ®Google Scholar
• Benloucif S, Galloway MP. Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur J Pharmacol 1991;200(1):1-8
   PubMed Web of Science ®Google Scholar
• Lucas G, De Deurwaerdere P, Caccia S, Umberto S. The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: opposite role of 5-HT(2A) and 5-HT(2C) receptor subtypes and significance of the haloperidol dose used. Neuropharmacology 2000;39(6):1053-63
   PubMed Web of Science ®Google Scholar
• Mayeux R. The ‘serotonin hypothesis’ for depression in Parkinson's disease. Adv Neurol 1990;53:163-6
   PubMedGoogle Scholar
• Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007;22(2):179-86
   PubMed Web of Science ®Google Scholar
• Iravani MM, Tayarani-Binazir K, Chu WB, et al. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability. J Pharmacol Exp Ther 2006;319(3):1225-34
   PubMed Web of Science ®Google Scholar
• Caretti V, Stoffers D, Winogrodzka A, et al. Loss of thalamic serotonin transporters in early drug-naive Parkinson's disease patients is associated with tremor: an [123;I]beta-CIT SPECT study. J Neural Transm 2008;115(5):721-9
   PubMed Web of Science ®Google Scholar
• Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990;87(5):1932-6
   PubMed Web of Science ®Google Scholar
• Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258(5090):1946-9
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 1998;21(12):521-8
   PubMed Web of Science ®Google Scholar
• Meschler JP, Howlett AC. Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology 2001;40(7):918-26
   PubMed Web of Science ®Google Scholar
• Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007;445(7128):643-7
   PubMed Web of Science ®Google Scholar
• Borgkvist A, Marcellino D, Fuxe K, et al. Regulation of DARPP-32 phosphorylation by Delta9-tetrahydrocannabinol. Neuropharmacology 2008;54(1):31-5
   PubMed Web of Science ®Google Scholar
• Greengard P, Allen PB, Nairn AC. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 1999;23(3):435-47
   PubMed Web of Science ®Google Scholar
• Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004;63(7):1245-50
   PubMed Web of Science ®Google Scholar
• Hancock DB, Martin ER, Stajich JM, et al. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol 2007;64(4):576-80
   PubMed Web of Science ®Google Scholar
• Kalda A, Yu L, Oztas E, Chen JF. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease. J Neurol Sci 2006;248(1-2):9-15
   PubMed Web of Science ®Google Scholar
• Schiffmann SN, Jacobs O, Vanderhaeghen JJ. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 1991;57(3):1062-7
   PubMed Web of Science ®Google Scholar
• Aoyama S, Kase H, Borrelli E. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci 2000;20(15):5848-52
   PubMed Web of Science ®Google Scholar
• Bing G, Zhang Y, Watanabe Y, et al. Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res 1994;668(1-2):261-5
   PubMed Web of Science ®Google Scholar
• Mavridis M, Degryse AD, Lategan AJ, et al. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 1991;41(2-3):507-23
   PubMed Web of Science ®Google Scholar
• Fulceri F, Biagioni F, Ferrucci M, et al. Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons. Brain Res 2007;1135(1):219-29
   PubMed Web of Science ®Google Scholar
• Pintor L, Bailles E, Valldeoriola F, et al. Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode. Gen Hosp Psychiatry 2006;28(1):59-64
   PubMed Web of Science ®Google Scholar
• Semba K, Fibiger HC, Vincent SR. Neurotransmitters in the mammalian striatum: neuronal circuits and heterogeneity. Can J Neurol Sci 1987;14(3 Suppl):386-94
   PubMed Web of Science ®Google Scholar
• Chen H, Jacobs E, Schwarzschild MA, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005;58(6):963-7
   PubMed Web of Science ®Google Scholar
• Blum-Degen D, Muller T, Kuhn W, et al. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995;202(1-2):17-20
   PubMed Web of Science ®Google Scholar
• Imamura K, Hishikawa N, Sawada M, et al. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol 2003;106(6):518-26
   PubMed Web of Science ®Google Scholar